US 2019/0315840 A1 · ANTI-DENGUE VIRUS ANTIBODIES, POLYPEPTIDES CONTAINING VARIANT FC REGIONS, AND METHODS OF USE

Abstract

The disclosure provides anti-DENV antibodies and methods of making and using the same. Nucleic acids encoding anti-DENV antibodies and host cells comprising the nucleic acids are also provided. The anti-DENV antibodies have uses that include treating DENV infection. The disclosure also provided polypeptides containing a variant Fc region and methods of making the same. Nucleic acids encoding polypeptides and host cells comprising the nucleic acids are also provided. The polypeptides have uses that include treating a viral infection. Also claimed is a polypeptide comprising a Fc variant comprising at least one amino acid alteration in Sa parent Fc region, wherein the variant Fc region has a substantially decreased FcYR-binding activity and does not have a substantially decreased C1q-binding activity when compared to the parent Fc region.

Claims30

Dependent claims

1-17. (canceled)

An isolated antibody that binds to dengue virus (DENV) E protein, wherein the antibody comprises:

(i) (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO:
11,
(b) HVR-H2 comprising the amino acid sequence of SEQ ID NO:
14,
(c) HVR-H3 comprising the amino acid sequence of SEQ ID NO:
17,
(d) HVR-L1 comprising the amino acid sequence of SEQ ID NO:
21,
(e) HVR-L2 comprising the amino acid sequence of SEQ ID NO:
24 and
(f) HVR-L3 comprising the amino acid sequence of SEQ ID NO:
27;
(ii) (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO:
11,
(b) HVR-H2 comprising the amino acid sequence of SEQ ID NO:
15,
(c) HVR-H3 comprising the amino acid sequence of SEQ ID NO:
17,
(d) HVR-L1 comprising the amino acid sequence of SEQ ID NO:
21,
(e) HVR-L2 comprising the amino acid sequence of SEQ ID NO:
24 and
(f) HVR-L3 comprising the amino acid sequence of SEQ ID NO:
27;
(iii) (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO:
11,
(b) HVR-H2 comprising the amino acid sequence of SEQ ID NO:
15,
(c) HVR-H3 comprising the amino acid sequence of SEQ ID NO:
18,
(d) HVR-L1 comprising the amino acid sequence of SEQ ID NO:
21,
(e) HVR-L2 comprising the amino acid sequence of SEQ ID NO:
24 and
(f) HVR-L3 comprising the amino acid sequence of SEQ ID NO:
27;
(iv) (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO:
11,
(b) HVR-H2 comprising the amino acid sequence of SEQ ID NO:
15,
(c) HVR-H3 comprising the amino acid sequence of SEQ ID NO:
19,
(d) HVR-L1 comprising the amino acid sequence of SEQ ID NO:
21,
(e) HVR-L2 comprising the amino acid sequence of SEQ ID NO:
24 and
(f) HVR-L3 comprising the amino acid sequence of SEQ ID NO:
27;
(v) (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO:
11,
(b) HVR-H2 comprising the amino acid sequence of SEQ ID NO:
15,
(c) HVR-H3 comprising the amino acid sequence of SEQ ID NO:
17,
(d) HVR-L1 comprising the amino acid sequence of SEQ ID NO:
21,
(e) HVR-L2 comprising the amino acid sequence of SEQ ID NO:
25 and
(f) HVR-L3 comprising the amino acid sequence of SEQ ID NO:
28;
(vi) (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO:
11,
(b) HVR-H2 comprising the amino acid sequence of SEQ ID NO:
15,
(c) HVR-H3 comprising the amino acid sequence of SEQ ID NO:
17,
(d) HVR-L1 comprising the amino acid sequence of SEQ ID NO:
22,
(e) HVR-L2 comprising the amino acid sequence of SEQ ID NO:
25 and
(f) HVR-L3 comprising the amino acid sequence of SEQ ID NO:
29;
(vii) (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO:
12,
(b) HVR-H2 comprising the amino acid sequence of SEQ ID NO:
15,
(c) HVR-H3 comprising the amino acid sequence of SEQ ID NO:
20,
(d) HVR-L1 comprising the amino acid sequence of SEQ ID NO:
23,
(e) HVR-L2 comprising the amino acid sequence of SEQ ID NO:
26 and
(f) HVR-L3 comprising the amino acid sequence of SEQ ID NO:
30;
or
(viii) (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO:
12,
(b) HVR-H2 comprising the amino acid sequence of SEQ ID NO:
15,
(c) HVR-H3 comprising the amino acid sequence of SEQ ID NO:
20,
(d) HVR-L1 comprising the amino acid sequence of SEQ ID NO:
21,
(e) HVR-L2 comprising the amino acid sequence of SEQ ID NO:
24 and
(f) HVR-L3 comprising the amino acid sequence of SEQ ID NO:
27.

94 more elements

An isolated antibody that binds to dengue virus (DENV) E protein, wherein the antibody comprises:

(i) VH comprising the amino acid sequence of SEQ ID NO:
2, VL comprising the amino acid sequence of SEQ ID NO:
7, CH comprising the amino acid sequence of SEQ ID NO:
46 and CL comprising the amino acid sequence of SEQ ID NO:
60,
(ii) VH comprising the amino acid sequence of SEQ ID NO:
3, VL comprising the amino acid sequence of SEQ ID NO:
7, CH comprising the amino acid sequence of SEQ ID NO:
46 and CL comprising the amino acid sequence of SEQ ID NO:
60,
(iii) VH comprising the amino acid sequence of SEQ ID NO:
3, VL comprising the amino acid sequence of SEQ ID NO:
7, CH comprising the amino acid sequence of SEQ ID NO:
54 and CL comprising the amino acid sequence of SEQ ID NO:
60,
(iv) VH comprising the amino acid sequence of SEQ ID NO:
3, VL comprising the amino acid sequence of SEQ ID NO:
7, CH comprising the amino acid sequence of SEQ ID NO:
59 and CL comprising the amino acid sequence of SEQ ID NO:
60,
(v) VH comprising the amino acid sequence of SEQ ID NO:
4, VL comprising the amino acid sequence of SEQ ID NO:
7, CH comprising the amino acid sequence of SEQ ID NO:
46 and CL comprising the amino acid sequence of SEQ ID NO:
60,
(vi) VH comprising the amino acid sequence of SEQ ID NO:
5, VL comprising the amino acid sequence of SEQ ID NO:
7, CH comprising the amino acid sequence of SEQ ID NO:
46 and CL comprising the amino acid sequence of SEQ ID NO:
60,
(vii) VH comprising the amino acid sequence of SEQ ID NO:
3, VL comprising the amino acid sequence of SEQ ID NO:
8, CH comprising the amino acid sequence of SEQ ID NO:
46 and CL comprising the amino acid sequence of SEQ ID NO:
60,
(viii) VH comprising the amino acid sequence of SEQ ID NO:
3, VL comprising the amino acid sequence of SEQ ID NO:
9, CH comprising the amino acid sequence of SEQ ID NO:
46 and CL comprising the amino acid sequence of SEQ ID NO:
60,
(ix) VH comprising the amino acid sequence of SEQ ID NO:
6, VL comprising the amino acid sequence of SEQ ID NO:
10, CH comprising the amino acid sequence of SEQ ID NO:
46 and CL comprising the amino acid sequence of SEQ ID NO:
60,
(x) VH comprising the amino acid sequence of SEQ ID NO:
6, VL comprising the amino acid sequence of SEQ ID NO:
10, CH comprising the amino acid sequence of SEQ ID NO:
59 and CL comprising the amino acid sequence of SEQ ID NO:
60,
(xi) VH comprising the amino acid sequence of SEQ ID NO:
6, VL comprising the amino acid sequence of SEQ ID NO:
7, CH comprising the amino acid sequence of SEQ ID NO:
46 and CL comprising the amino acid sequence of SEQ ID NO:
60,
(xii) VH comprising the amino acid sequence of SEQ ID NO:
6, VL comprising the amino acid sequence of SEQ ID NO:
7, CH comprising the amino acid sequence of SEQ ID NO:
54 and CL comprising the amino acid sequence of SEQ ID NO:
60, or
(xiii) VH comprising the amino acid sequence of SEQ ID NO:
6, VL comprising the amino acid sequence of SEQ ID NO:
7, CH comprising the amino acid sequence of SEQ ID NO:
59 and CL comprising the amino acid sequence of SEQ ID NO:
60.

62 more elements

Dependencies are inferred from the claim text.

Facts

Application

16/435,979Filed 10 Jun 2019

Priority

SG 10201607778X16 Sep 2016

Published

17 Oct 2019

Term ends

Not estimatedThe source records don’t support an estimate.

Classification13 codes

C07K 16/116
RNA viruses: togaviridae ; Matonaviridae ; Flaviviridae
A61P 31/12
Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics: antivirals
A61K 2039/505
Medicinal preparations containing antigens or antibodies: comprising antibodies
C07K 2317/52
Characterized by immunoglobulin fragments: constant or Fc region; Isotype

Anti-dengue virus antibodies, polypeptides containing variant fc regions, and methods of use

Life of this patent

Anti-dengue virus antibodies, polypeptides containing variant fc regions, and methods of use

Life of this patent

Abstract

Claims30